{"id":3901,"date":"2025-03-31T18:11:52","date_gmt":"2025-03-31T18:11:52","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/deferiprone-txt\/"},"modified":"2025-03-31T18:11:52","modified_gmt":"2025-03-31T18:11:52","slug":"deferiprone-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/deferiprone-txt\/","title":{"rendered":"Deferiprone.txt"},"content":{"rendered":"

Deferiprone<\/h1>\n

CLINICAL USE <\/H3>
\nOrally administered chelator:Treatment of transfusional iron overload

DOSE IN NORMAL RENAL FUNCTION <\/H3>25 mg\/kg 3 times daily. Maximum 100 mg\/kg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :139.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 15 \u2013 see Other Information<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.55\u20131.73<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20133\/Unknown

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Give 50% of dose and monitor
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Give 50% of dose and monitor

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Deferiprone is hepatically metabolised (>85%) to predominantly glucuronide conjugates (no chelating activity). Deferiprone, the glucuronide conjugates, and deferiprone-complexed iron are cleared principally by the kidney, with 80% of the dose recovered in the urineSide effects include reversible neutropenia, agranulocytosis, musculoskeletal and joint pain, subclinical ototoxicity, plus case reports of systemic vasculitis and fatal SLECan cause subnormal serum zinc levels Reddish-brown discolouration of the urine reported in 40% of thalassaemia patients undergoing deferiprone therapyDeferiprone removed aluminium in vitro from blood samples of 46 patients undergoing chronic haemodialysis. Only patients with serum aluminium concentrations >80 mcg\/mL were included. Deferiprone removed the aluminium faster and more effectively from higher molecular weight proteins than desferrioxamine. (Canteros-Piccotto MA, Fern\u00e1ndez-Martin JL, Cannata-Ortiz MJ, et al. Effectiveness of deferiprone (L1) releasing the aluminium bound to plasma proteins in chronic renal failure.
    \n","protected":false},"excerpt":{"rendered":"

    Deferiprone CLINICAL USE Orally administered chelator:Treatment of transfusional iron overload<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3901","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3901"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3901\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}